Introduction Scaling a GLP-1 analog from preclinical synthesis to Good Manufacturing Practice (GMP) kilogram-scale manufacturing involves moving beyond small-scale discovery […]
Introduction Single-Use Systems and GMP Extractables and Leachables (E&L) Testing establishes the analytical foundation necessary for detecting, identifying, quantifying, and
Introduction Designing a GMP-Compliant Extractables and Leachables (E&L) Study requires a structured, risk-based approach that brings together advanced analytical chemistry,
Introduction: Analytical characterization of peptide-oligonucleotide conjugates becomes significantly more complex once a molecule moves from a single-linker design to a
Introduction Supporting a poorly soluble generic API requires an integrated Chemistry, Manufacturing, and Controls (CMC) framework that combines systematic reference-listed
Introduction Executing a successful Generic Metered Dose Inhaler (MDI) ANDA Development program requires a comprehensive weight-of-evidence regulatory framework that demonstrates
Introduction Impurity profiling and structural elucidation for generic small-molecule injectable Abbreviated New Drug Applications (ANDAs) is an essential analytical activity
Introduction: GMP-Grade PLGA for Phase II/III Clinical Supply is a critical CMC decision for pharmaceutical companies developing long-acting injectables, microspheres,
Introduction Accelerating Health Canada ANDS Submission timelines requires a coordinated regulatory strategy that integrates pre-filing bioequivalence data verification, technical auditing
Introduction Bioanalytical Method Development and Validation at a CDMO provides the quantitative foundation needed to establish pharmacokinetic equivalence between generic
